论文部分内容阅读
目的:探讨自体细胞因子诱导杀伤(CIK)细胞联合化疗方案治疗老年急性白血病的临床疗效。方法:采集6例在我院进行化疗治疗的老年急性白血病患者的静脉血制备自体CIK细胞,成熟后回输入体内,持续注射10天为一个疗程。观察培养前和培养13天后白细胞各亚型细胞所占百分比,并比较CIK细胞回输前后患者白细胞亚群、感染次数及输血量的变化。结果:培养后CD3~+、CD8~+、CD3~+CD8~+、CD3~+CD56~+亚型细胞百分比均显著高于培养前(P<0.05),CIK细胞回输后患者体内CD3~+、CD3~+CD8~+、CD3~+CD56~+亚群细胞百分比显著高于回输前(P<0.05);CIK细胞回输后,患者感染次数和持续时间均显著少于回输前(P<0.05),疾病稳定期输血量显著低于回输前(P<0.05),疾病进展期输血量与回输前差异无显著性意义(P>0.05)。结论:自体CIK细胞联合化疗治疗老年急性白血病患者有效且安全,可维持病情的稳定、提高机体细胞免疫功能和抗感染能力,值得临床推广。
Objective: To investigate the clinical efficacy of autologous cytokine-induced killer (CIK) cells combined with chemotherapy in the treatment of senile acute leukemia. Methods: 6 cases of elderly patients with acute leukemia chemotherapy in our hospital collected from patients with ventricular blood CIK cells, mature back into the body, continuous injection of 10 days for a course of treatment. The percentages of leukocyte subtypes before and 13 days after culture were observed. The leukocyte subsets, infection times and blood transfusion volume were compared before and after CIK cells were transfused. Results: The percentages of CD3 ~ +, CD8 ~ +, CD3 ~ + CD8 ~ + and CD3 ~ + CD56 ~ + subtypes in cultured cells were significantly higher than those before culture (P <0.05) +, CD3 ~ + CD8 ~ + and CD3 ~ + CD56 ~ + subpopulations were significantly higher than those before reinfusion (P <0.05). After CIK cells were transfused, the frequency and duration of infection were significantly less than those before reinfusion (P <0.05). The amount of blood transfusion in stable period was significantly lower than that before reperfusion (P <0.05). There was no significant difference between the amount of blood transfusion and the level before transfusion (P> 0.05). Conclusion: The combination of autologous CIK cells and chemotherapy in the treatment of elderly patients with acute leukemia is effective and safe, can maintain the stability of the disease, improve the cellular immunity and anti-infective ability of the body, and is worthy of clinical promotion.